Risk-benefit assessment of angiotensin II receptor antagonists

By Shusterman Neil  

Expert Opinion on Drug Safety, Vol. 1, Iss. 2, 2002-07 ,pp. : 137-152

Informa Healthcare

Access to resources Recommend Favorite

Transient Receptor Potential Vanilloid 1 and Xenobiotics

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 7, Iss. 2, 2008-04 ,pp. : 159-171

Bentham Science Publishers

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Inhaled Long-Acting β 2 -Agonists in the Management of Obstructive Pulmonary Disease

By Sovani Milind P.   Whale Christopher I.   Tattersfield Anne. E.  

Drug Safety, Vol. 27, Iss. 10, 2004-01 ,pp. : 689-715

Adis International

Access to resources Recommend Favorite

Biologically Bounded Risk Assessment for Receptor-Mediated Nongenotoxic Carcinogens

By Gastel J.A.   Sutter T.R.  

Regulatory Toxicology and Pharmacology, Vol. 22, Iss. 3, 1995-12 ,pp. : 273-282

Academic Press

Access to resources Recommend Favorite

A partial agonist model used in the allosteric modulation of the NMDA receptor - II. Assessment of the antinociceptive activity of combinations of competitive and non-competitive NMDA antagonists with agents acting at allosteric-glycine and polyamine receptor sites

By Robichon R.   Randall P.K.   Leslie S.W.  

European Journal of Pharmacology, Vol. 328, Iss. 2, 1997-09 ,pp. : 255-263

Elsevier

Access to resources Recommend Favorite